Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

Journal of Clinical Oncology

Volumn 22, Issue 9, 2004, Pages 1589-1597

  Hanna, Nasser ^a   Shepherd, Frances A ^b   Fossella, Frank V ^b   Pereira, Jose R ^b   Demarinis, Filippo ^b   Von Pawel, Joachim ^b   Gatzemeier, Ulrich ^b   Tsao, Thomas Chang Yao ^b   Pless, Miklos ^b   Muller, Thomas ^b   Lim, Hong Liang ^b   Desch, Christopher ^b   Szondy, Klara ^b   Gervais, Radj ^b   Shaharyar, ^b   Manegold, Christian ^b   Paul, Sofia ^b   Paoletti, Paolo ^b   Einhorn, Lawrence ^b   Bunn Jr , Paul A ^b  

^a INDIANA UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; DEXAMETHASONE; DOCETAXEL; FOLIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; PEMETREXED; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; TAXOID;

ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEBRILE NEUTROPENIA; HOSPITALIZATION; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADULT; AGED; CHEMICALLY INDUCED DISORDER; FEMALE; LUNG TUMOR; MALE; MIDDLE AGED; PATHOLOGY; PHASE 3 CLINICAL TRIAL; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 2442661845     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.08.163     Document Type: Article

References (18)

1. Parkin DM, Bray FI, Devessa SS: Cancer burden for the year 2000: The global picture. Eur J Cancer 37:S4-S66, 2001 (suppl 8)
2. Stephens R, Fairlamb D, Gower N, et al: The Big Lung Trial (BLT): Determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC): Preliminary results in the supportive care setting. Proc Am Soc Clin Oncol 21:291a, 2002 (abstr 1161)
3. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer-A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311:899-909, 1995
4. Grilli R, Oxyman A, Julian J: Chemotherapy for advanced non-small cell lung cancer: How much benefit is enough? J Clin Oncol 11:1866-1872, 1993
5. Shepherd F, Dancey J, Ramlau R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103, 2000
6. Fossella F, DeVore R, Kerr R, et al: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354-2362, 2000
7. Clarke S, Boyer M, Millward M, et al: Phase II study of LY231514, a multi-targeted antifolate. in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 16:465a, 1997 (abstr 1670)
8. Rusthoven J, Eisenhauer E, Butts C, et al: Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small cell lung cancer: A Phase II study-National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:1194-1199, 1999
9. Smit E, Mattson K, von Pawel J, et al: ALIMTA (pemetrexed disodium) as second-line treatment of non-small cell lung cancer: A phase II study. Ann Oncol 14:455-460, 2003
10. Vogelzang N, Rusthoven J, Symanowski, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636-2644, 2003
11. Bunn P, Paoletti P, Niyikiza C, et al: Vitamin B12 and folate reduce toxicity of Alimta (Pemetrexed Disodium. LY231514, MTA) a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol 20:76a, 2001 (abstr 300)
12. Adjei AA: Current data with pemetrexed (Alimta) in non-small cell lung cancer. Clin Lung Cancer 4:S64-S67, 2003 (suppl 2)
13. Hollen PJ, Gralla RJ, Kris MG, et al: Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies: Psychometric assessment of the Lung Cancer Symptom Scale. Cancer 73:2087-2098, 1994
14. Rothmann M, Li N, Chen G. et al: Design and analysis of non-inferiority mortality trials in oncology. Stats in Med 22:239-264, 2003
15. Leemis LM, Trivedi KS: A comparison of approximate interval estimators for the Bernoulli parameter. Am Stat 50:63-68, 1996
16. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
17. Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253, 1992
18. Norman G, Sloan J, Wyrwich K: Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Med Care 41:582-592, 2003